<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.pharmacytimes.com/view/when-medicine-changes-faster-than-health-care-preparing-for-a-new-era</loc>
      <lastmod>2026-11-17T15:08:08.791Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T15:08:08.791Z</news:publication_date>
        <news:title><![CDATA[When Medicine Changes Faster Than Health Care: Preparing for a New Era ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/from-hospital-to-home-medication-reconciliation-rehab-transitions-and-pharmacist-led-patient-navigation</loc>
      <lastmod>2026-11-17T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T15:00:00Z</news:publication_date>
        <news:title><![CDATA[From Hospital to Home: Medication Reconciliation, Rehab Transitions, and Pharmacist-Led Patient Navigation]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/giredestrant-plus-everolimus-wins-fda-approval-in-esr1-mutated-advanced-breast-cancer</loc>
      <lastmod>2026-11-16T22:53:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T22:53:00Z</news:publication_date>
        <news:title><![CDATA[Giredestrant Plus Everolimus Wins FDA Approval in ESR1-Mutated Advanced Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/pharmacists-key-to-mavacamten-rems-interaction-checks-in-teens</loc>
      <lastmod>2026-11-16T21:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Pharmacists Key to Mavacamten REMS, Interaction Checks in Teens]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/fda-approves-gefurulimab-as-first-once-weekly-self-administered-c5-inhibitor-for-gmg</loc>
      <lastmod>2026-11-16T20:53:43.674Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T20:53:43.674Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Gefurulimab as First Once-Weekly, Self-Administered C5 Inhibitor for gMG]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/semaglutide-associated-sensory-skin-disturbance-in-patients-without-diabetes-treated-for-weight-loss</loc>
      <lastmod>2026-11-16T20:53:09.603Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T20:53:09.603Z</news:publication_date>
        <news:title><![CDATA[Semaglutide-Associated Sensory Skin Disturbance in Patients Without Diabetes Treated for Weight Loss]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/sno-2026-vorasidenib-updates-highlight-seizure-control-in-idh-mutant-glioma</loc>
      <lastmod>2026-11-16T18:53:38.888Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T18:53:38.888Z</news:publication_date>
        <news:title><![CDATA[SNO 2026: Vorasidenib Updates Highlight Seizure Control in IDH-Mutant Glioma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/blood-glucose-testing-when-nonadherence-isn-t-the-real-issue</loc>
      <lastmod>2026-11-16T18:26:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T18:26:00Z</news:publication_date>
        <news:title><![CDATA[Blood Glucose Testing: When Nonadherence Isn't the Real Issue]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/dexmedetomidine-receives-fda-approval-for-acute-treatment-for-agitation-associated-with-schizophrenia</loc>
      <lastmod>2026-11-16T17:48:11.175Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T17:48:11.175Z</news:publication_date>
        <news:title><![CDATA[Dexmedetomidine Receives FDA Approval for Acute Treatment for Agitation Associated With Schizophrenia]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/fda-approves-pertuzumab-biosimilar-for-her2-positive-breast-cancer</loc>
      <lastmod>2026-11-16T16:35:30.142Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:35:30.142Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Pertuzumab Biosimilar for HER2-Positive Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/recognizing-the-signs-identifying-patients-at-risk-for-recurrent-stroke-or-tia</loc>
      <lastmod>2026-11-16T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Recognizing the Signs: Identifying Patients at Risk for Recurrent Stroke or TIA]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/fda-approves-obinutuzumab-for-primary-membranous-nephropathy</loc>
      <lastmod>2026-11-16T14:19:23.122Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T14:19:23.122Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Obinutuzumab for Primary Membranous Nephropathy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/structured-blood-glucose-testing-why-timing-matters</loc>
      <lastmod>2026-11-15T16:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Pharmacy Times</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-15T16:30:00Z</news:publication_date>
        <news:title><![CDATA[Structured Blood Glucose Testing: Why Timing Matters]]></news:title>
      </news:news>
	</url></urlset>